33 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells, resulting in the release
8-K
EX-99.1
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
administered valacyclovir into a toxic metabolite that kills nearby cancer cells, resulting in the release of a wide variety of cancer antigens. At the same
8-K
EX-99.1
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
, systemic immune response against the disease. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite
8-K
EX-99.1
CADL
Candel Therapeutics Inc
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
the disease. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together
8-K
EX-99.1
a2lg1 namhlpp9ium
28 Nov 23
Cost Associated with Exit or Disposal Activities
9:00am
8-K
EX-99.1
v0bn rviws6ruw
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
8-K
EX-99.1
izxh13o1 t4j
26 Sep 23
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
azxfixzufck
13 Jun 23
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC
8:31am
8-K
EX-99.1
9u0048
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
4t9p hwzzd0i
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
yqykn7y4sfo27b2q9
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
o4sbpfbrp64nu07dm
14 Nov 22
Other Events
9:26am
S-3
EX-1.2
zbdl21y1 v2zc3t
5 Aug 22
Shelf registration
5:08pm